Company Overview of Theraclone Sciences, Inc.
Theraclone Sciences, Inc., a discovery-stage biopharmaceutical company, engages in the discovery and development of monoclonal antibody therapeutics for the treatment of infectious diseases and inflammation. The company focuses on identifying rare fully human antibodies from immunologically relevant human subjects by using its proprietary antibody discovery technology, I-STAR (In-Situ Therapeutic Antibody Rescue). It has a portfolio of antibody programs at preclinical and clinical development stage targeting various medical conditions, including influenza, HIV, other bacterial targets, breast cancer, and infectious disease-associated cancers. Theraclone Sciences, Inc. has strategic collabora...
1124 Columbia Street
Seattle Life Sciences Building
Seattle, WA 98104
Founded in 2004
Key Executives for Theraclone Sciences, Inc.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Theraclone Sciences, Inc. Key Developments
Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM
Jan 29 15
Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015
Jan 19 15
Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015. Venue: The Waldorf Astoria, New York, New York, United States. Presentation Date & Speakers: Feb-10-2015, Clifford J. Stocks, Chief Executive Officer and Director.
Theraclone Sciences Announces Licenses Agreement with Gilead Sciences
Aug 1 14
Theraclone Sciences, Inc. has entered into a license agreement with Gilead Sciences, Inc. to develop and commercialize products incorporating Theraclone's broadly neutralizing human immunodeficiency virus (HIV)-antibodies for therapeutic applications in HIV. Both the companies are based in the US. Under the terms of the transaction, Theraclone will receive an upfront payment and is eligible to receive additional payments based upon achievement of certain development and commercialization milestones.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 30, 2015